A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07599761
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-722 — DRUG
    Oral Tablet
  • Itraconazole — DRUG
    Oral Capsule

Study Details

The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.

Key Dates

Start date
May 5, 2026
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Period 1 & 2
    In Period 1, participants will receive a single dose of ABBV-722. In Period 2, participants will receive multiple daily doses of Itraconazole and a single dose of ABBV-722.

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) of ABBV-722 [ Time Frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 282143GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies